medRxiv
April 7, 2021
David E. Gard, Mollie Pleet, Ellen Bradley et al.
preprint
Abstract Objective: Given the treatment limitations of depression in bipolar disorder, we evaluated the known risks of using psilocybin (and similar substances) in this population, including a systematic assessment of published case histories, to assess the risk of psilocybin as a treatment of depression in bipolar disorder. Data Sources: A comprehensive search of case studies published through...
Clinical Case Reports
April 4, 2021
Terry Schwartz, Mary Ellen Trunko, David Feifel et al.
52 citations
Abstract Severe and enduring eating disorders (EDs) have the highest mortality rate of all psychiatric illnesses (Arch Gen Psychiatry, 2011, 68 , 724), especially when comorbid with treatment‐resistant depression (TRD) (Psychiatr Res, 2016, 244 , 45). We report on four patients with enduring EDs and TRD treated with repeat ketamine over 12 + months, showing improvement in depression with only...
Biological Psychiatry Global Open Science
April 1, 2021
Yujing Zhang, Bing Xie, Yin Yuan et al.
Background Poststroke social isolation could worsen poststroke depression and dampen neurogenesis. (R,S)-ketamine has antidepressant and neuroprotective effects; however, its roles and mechanisms in social isolation–mediated depressive-like behaviors and sensorimotor recovery remain unclear. Methods Mice were subjected to transient middle cerebral artery occlusion, and then were pair-housed...
European Psychiatry
April 1, 2021
M. Trigo
Introduction Depression is one of the most prevalent mental illnesses, leading to important personal distress and economic consequences. Treatment is long, often involving psychotherapy and pharmacological treatment, and relapses are frequent. Used mostly for treatment of mood disorders and alcohol dependence, drugs such as lysergic acid diethylamide (LSD) were studied in the 1950’s and showed...
The Journal of family practice
April 1, 2021
Amanda Zorn, Sean Linn, Mat Jenkinson et al.
5 citations
MAYBE, but it's too soon to tell. There is limited evidence that ketamine by itself is effective in the very short term. Single-dose intravenous (IV) ketamine is more likely than placebo (odds ratio = 11-13) to produce improvement (> 50%) in standardized depression scores in 1 to 3 days, lasting up to a week. Twice- or thriceweekly IV ketamine improves symptom scores by 20%-25% over 2 weeks...
CNS Spectrums
April 1, 2021
Steve Best, Dan G. Pavel, Natalie Haustrup
1 citation
AbstractBackgroundRepetitive transcranial magnetic stimulation (rTMS) is a safe, effective and non-invasive treatment for many psychiatric illnesses, including treatment-resistant depression (TRD). Ketamine, an NMDA receptor antagonist, is also an effective antidepressant. This retrospective review examined the clinical benefits of combining these two established treatments for patients...
European Psychiatry
April 1, 2021
A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira et al.
1 citation
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression (TRD). Novel antidepressants with rapid and sustained effects on mood and cognition could...
The Open Public Health Journal
March 22, 2021
Ormanee Patarathipakorn, Manyat Ruchiwit, Marlaine Smith
Background: The increased amount of depression among people with diabetes is a burden on society. Biofeedback and meditation can impact the self-regulation of this group. Objective: This study aims to study the effect of combining meditation with a biofeedback training program on the stress and depression among diabetes people with mild depression. Methods: This study is based on a randomized...
Frontiers in Psychology
March 22, 2021
Mohamed Al-Refae, Amr Al-Refae, Melanie Munroe et al.
Introduction: Many individuals and families are currently experiencing a high level of COVID-19-related stress and are struggling to find helpful coping mechanisms. Mindfulness-based interventions are becoming an increasingly popular treatment for individuals experiencing depression and chronic levels of stress. The app (Serene) draws from scholarly evidence on the efficacy of mindfulness...
BMC Neurology
March 21, 2021
Torsten Sauder, Philipp M Keune, Roy Müller et al.
Abstract Objectives Persons with MS (PwMS) often display symptoms of depression and fatigue. Mindfulness-based interventions are known to counteract these symptoms. However, to-date the exact relations between trait mindfulness, depression and fatigue remain to be examined. Fatigue is generally regarded as a symptom immanent to the disease and as a direct neurobiological consequence of...